Shasun Pharmaceuticals Limited(BSE:524552 NSE:SHASUNPHAR) ,Company Snapshot, Recent Developments, Latest News, Financials, Price Charts, Ratios, Contact Information

Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals

Home

News Centre

IPO

Markets	Companies	Research	Industries	E-Mail Page

my Last 5 Scrips
Company	BSE Price(Rs)	% Chg
Ntpc Ltd	150.25	1.08
Tata Stl	313.15	4.56
State Ba	2151.15	1.15
Tata Mot	288.10	0.93
Hindalco	107.10	1.70
Clear All	Clear Last

NSE Live
Nifty Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

BSE Live
BSE30 Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

Market Pulse
Leaders Laggards FII Activity Mutual Fund Activity Meetings

Results Watch
Results Calendar Results Announced

IPO Watch

Company
Snapshots Quotes Charts Financials Recent News Broker Research Meetings Research Tutorial Discussion Forum

Research
Research Reports

Sector Watch

Economy Watch

Snapshot-Shasun Pharmaceuticals Limited

Shasun Pharmaceuticals Limited

Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524552	NSE:SHASUNPHAR	Bloomberg:SSCD@IN	Reuters:SHAS.BO
Market Lot: 1	Face Value: 2	ISIN Demat: INE317A01028

Quotes	Snapshot	Charts	Financials	Research	Recent News
Peer Group	AGM/AM	MF Holding	Discussion Forum	BSE/NSE Notices	BSE/NSE Deals

Recent Developments
22-MAR-12 Shasun Pharmaceuticals announced that the extraordinary general meeting of shareholders has approved the preferential allotment to Caduceus Mauritius Asia Limited (CAML), a wholly owned subsidiary of OrbiMed Asia Partners 25-APR-11 Shasun Pharmaceuticals one of the largest producers of ibuprofen worldwide has confirmed that the company has been permitted to resume the operations at Cuddalore factory (Tamil nadu) today. 09-MAR-11 Sh... More..
Business Profile	Future Plans

CEO Talk

Shasun to grow at 15%to18% S. Vimal Kumar

One To One

Latest News

Shasun Pharma signs licensing pact with Debiopharm -IRIS 10-Apr-13

Brief Financials (in Rs. Mn.)

Detailed Quarterly

Period ending (months)	31-Dec-2012(9)	31-Mar-2012 (12)	31-Mar-2011 (12)
Net sales	5326.00	6879.50	5441.10
Other Income	196.50	409.60	144.50
Total Income	5522.50	7289.10	5585.60
Cost of goods sold	5346.30	6843.90	5286.90
OPBDIT	176.20	445.20	298.70
PAT	160.00	530.60	48.80
Gross Block	-	-	-
Equity capital	110.30	110.30	97.10
EPS (Rs.)	-	10.92	1.00
DPS (Rs.)	-	-	-
BV (Rs.)	-	-	-
P/E range (x)	-	3.49 - 8.38	48.60 - 100.90
Debt / Equity (x)	-	-	-
Operating margin (% of OI)	3.2	6.1	5.3
Net margin (% of OI)	2.9	7.3	0.9